{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:15:57Z","timestamp":1768410957673,"version":"3.49.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.4161\/hv.23412","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T17:12:42Z","timestamp":1359565962000},"page":"858-864","source":"Crossref","is-referenced-by-count":30,"title":["Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax<sup>\u00ae<\/sup>) in individuals aged \u2265 70 years: A randomized study of a single dose vs. two different two-dose schedules"],"prefix":"10.1080","volume":"9","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"R\u00fcmke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Icardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Sadorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Fiquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,11,6]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/0002512-200825120-00002","article-title":"Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient","volume":"25","author":"Johnson","year":"2008","journal-title":"Drugs Aging"},{"key":"R2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF03324909","article-title":"Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination","volume":"21","author":"Johnson","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"R3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"R4","first-page":"571","article-title":"Postherpetic neuralgia","volume":"25","author":"Hope-Simpson","year":"1975","journal-title":"J R Coll Gen Pract"},{"key":"R5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Schmader","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R6","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1086\/522152","article-title":"The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine","volume":"197","author":"Schmader","year":"2008","journal-title":"J Infect Dis"},{"key":"R7","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/jmv.10316","article-title":"A study of shingles and the development of postherpetic neuralgia in East London","volume":"70","author":"Scott","year":"2003","journal-title":"J Med Virol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF02770836","article-title":"A prognostic score for postherpetic neuralgia in ambulatory patients","volume":"26","author":"Meister","year":"1998","journal-title":"Infection"},{"key":"R9","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1212\/WNL.45.12_Suppl_8.S52","article-title":"Herpes zoster and quality of life: a self-limited disease with severe impact","volume":"45","author":"Lydick","year":"1995","journal-title":"Neurology"},{"key":"R10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin J Pain"},{"key":"R11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"R12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10389-010-0323-0","article-title":"Impact of herpes zoster and post-herpetic neuralgia on patients\u2019 quality of life: a patient-reported outcomes survey","volume":"18","author":"Weinke","year":"2010","journal-title":"Z Gesundh Wiss"},{"key":"R13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-4933-4-9","article-title":"Challenges for vaccination in the elderly","volume":"4","author":"Aspinall","year":"2007","journal-title":"Immun Ageing"},{"key":"R14","unstructured":"Arvin AM. Varicella-zoster virus. In DM Knipe, PM Howley, Eds. Fields Virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, PA, 2001: 2731-68."},{"key":"R15","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"R16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"key":"R17","unstructured":"Strauss S, Oxman MN, Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick' s Dermatology in General Medicine. 5th ed. Vol 2. New York, NY: McGraw-Hill; 1999:2427-50."},{"key":"R18","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737175.7.11.1581","article-title":"Postherpetic neuralgia: epidemiology, pathophysiology and management","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"R19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00002508-200211000-00002","article-title":"Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy","volume":"18","author":"Schmader","year":"2002","journal-title":"Clin J Pain"},{"key":"R20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/421942","article-title":"Acute pain in herpes zoster and its impact on health-related quality of life","volume":"39","author":"Katz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R21","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jpain.2007.10.008","article-title":"Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"R22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11206290-000000000-00000","article-title":"Zoster vaccine (Zostavax\u00ae): a guide to its use in preventing herpes zoster and postherpetic neuralgia","volume":"27","author":"Anon.","year":"2011","journal-title":"Drugs Ther Perspect"},{"key":"R23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/infdis\/166.2.253","article-title":"Immune response of elderly individuals to a live attenuated varicella vaccine","volume":"166","author":"Levin","year":"1992","journal-title":"J Infect Dis"},{"key":"R24","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/WNL.45.12_Suppl_8.S41","article-title":"Immunization to reduce the frequency and severity of herpes zoster and its complications","volume":"45","author":"Oxman","year":"1995","journal-title":"Neurology"},{"key":"R25","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1086\/514264","article-title":"Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect","volume":"178","author":"Levin","year":"1998","journal-title":"J Infect Dis"},{"key":"R26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"R27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0264-410X(99)00510-1","article-title":"Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial","volume":"18","author":"Trannoy","year":"2000","journal-title":"Vaccine"},{"key":"R28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"R31","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","article-title":"Vaccination against herpes zoster and postherpetic neuralgia","volume":"197","author":"Oxman","year":"2008","journal-title":"J Infect Dis"},{"key":"R32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"R33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"R34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"R35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"key":"R36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs Aging"},{"key":"R37","unstructured":"CPMP 1997 Note For Guidance On Good Clinical Practice. (CPMP\/ICH\/135\/95), 1997. Accessed on 05 Jan 2011 at: http:\/\/www.ema.europa.eu\/pdfs\/human\/ich\/013595en.pdf"},{"key":"R38","unstructured":"WMA 2010 World Medical Association Declaration Of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Accessed on 05 Jan 2011 at: http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html"},{"key":"R39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0264-410X(96)00107-7","article-title":"Comparison of gpELISA and neutralizing antibody responses to Oka\/Merck live varicella vaccine (Varivax) in children and adults","volume":"15","author":"Krah","year":"1997","journal-title":"Vaccine"},{"key":"R40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17469872.1.4.607","article-title":"Herpes zoster and postherpetic neuralgia","volume":"1","author":"Guenther","year":"2006","journal-title":"Expert Review of Dermatology"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.23412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T06:40:51Z","timestamp":1498027251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.23412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.4161\/hv.23412"],"URL":"https:\/\/doi.org\/10.4161\/hv.23412","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}